CN102762229B9 - 适用于用疏水pet试剂pet成像的配方 - Google Patents
适用于用疏水pet试剂pet成像的配方 Download PDFInfo
- Publication number
- CN102762229B9 CN102762229B9 CN201080059126.6A CN201080059126A CN102762229B9 CN 102762229 B9 CN102762229 B9 CN 102762229B9 CN 201080059126 A CN201080059126 A CN 201080059126A CN 102762229 B9 CN102762229 B9 CN 102762229B9
- Authority
- CN
- China
- Prior art keywords
- alcohol
- alkyl
- formulation
- compound
- polyether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 230000002209 hydrophobic effect Effects 0.000 title claims description 12
- 238000009472 formulation Methods 0.000 title abstract description 84
- 238000012879 PET imaging Methods 0.000 title description 4
- 238000012636 positron electron tomography Methods 0.000 title 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims abstract description 37
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims abstract description 30
- 239000003446 ligand Substances 0.000 claims abstract description 30
- 235000021286 stilbenes Nutrition 0.000 claims abstract description 30
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 27
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 16
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 16
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- -1 -(C1-C4) Alkyl oxygen Chemical compound 0.000 claims description 39
- 229920000570 polyether Polymers 0.000 claims description 27
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 229940125904 compound 1 Drugs 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 229940125782 compound 2 Drugs 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 claims description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 claims description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 24
- 235000010323 ascorbic acid Nutrition 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 239000011668 ascorbic acid Substances 0.000 description 12
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002600 positron emission tomography Methods 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000003840 hydrochlorides Chemical class 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229940047035 ascorbic acid 20 mg Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IQUWAPNUQVLWGG-GFCCVEGCSA-N [5-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypyridin-3-yl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=NC=1)C(=O)N1C[C@@H](CC1)N IQUWAPNUQVLWGG-GFCCVEGCSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005376 alkyl siloxane group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
成分 | 配方I |
化合物1 | 54μgHCl(50μg碱,化合物1) |
乙醇96% | 1.2075g |
聚乙二醇(PEG 400) | 2g |
抗坏血酸 | 20mg |
磷酸一氢钠-二水合物 | 26.7mg |
磷酸二氢钠-二水合物 | 93.6mg |
水 | 加至10g |
pH | 6.8左右 |
成分 | 配方II |
化合物1 | 55.1μg HCl |
乙醇96% | 1.215g |
聚乙二醇(PEG 400) | 2g(约1.8mL) |
抗坏血酸 | 20mg |
磷酸一氢钠-二水合物 | 25mg |
水 | 加至10mL |
pH | 6.84 |
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075568.7 | 2009-12-23 | ||
EP09075568 | 2009-12-23 | ||
PCT/EP2010/070455 WO2011076825A1 (en) | 2009-12-23 | 2010-12-22 | Formulations suitable for pet imaging with hydrophobic pet agents |
Publications (3)
Publication Number | Publication Date |
---|---|
CN102762229A CN102762229A (zh) | 2012-10-31 |
CN102762229B CN102762229B (zh) | 2014-11-12 |
CN102762229B9 true CN102762229B9 (zh) | 2020-12-01 |
Family
ID=43797709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080059126.6A Active CN102762229B9 (zh) | 2009-12-23 | 2010-12-22 | 适用于用疏水pet试剂pet成像的配方 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120328521A1 (zh) |
EP (1) | EP2515948A1 (zh) |
JP (1) | JP5774023B2 (zh) |
KR (1) | KR20120098914A (zh) |
CN (1) | CN102762229B9 (zh) |
AR (1) | AR079687A1 (zh) |
AU (1) | AU2010334929B2 (zh) |
BR (1) | BR112012015369A2 (zh) |
CA (1) | CA2785576C (zh) |
EA (1) | EA022447B1 (zh) |
HK (1) | HK1178064A1 (zh) |
IL (1) | IL220569A0 (zh) |
MX (1) | MX336896B (zh) |
SG (1) | SG181903A1 (zh) |
TW (1) | TW201138833A (zh) |
UY (1) | UY33152A (zh) |
WO (1) | WO2011076825A1 (zh) |
ZA (1) | ZA201204683B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6081997B2 (ja) * | 2011-06-21 | 2017-02-15 | ピラマル イメージング ソシエテ アノニム | Petイメージングに適したフッ素化スチルベンの製剤 |
US20170176469A1 (en) * | 2012-02-24 | 2017-06-22 | Case Western Reserve University | Molecular Probes for Detecting Lipids |
CA2869398C (en) * | 2012-04-10 | 2019-10-22 | Lantheus Medical Imaging, Inc. | Radiopharmaceutical synthesis methods |
EP3426309B1 (en) | 2016-03-09 | 2022-05-04 | Case Western Reserve University | Radioligands for myelin |
TW201906818A (zh) * | 2017-05-31 | 2019-02-16 | 美商511製藥公司 | 新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用 |
CA3088232A1 (en) * | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics |
JPWO2020202831A1 (zh) * | 2019-03-29 | 2020-10-08 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185793A1 (en) * | 2000-03-13 | 2003-10-02 | Felix Kratz | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
CN101123995A (zh) * | 2004-12-17 | 2008-02-13 | 宾夕法尼亚大学理事会 | 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0823894A1 (en) * | 1995-05-01 | 1998-02-18 | University Of Pittsburgh | Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
WO2002043765A2 (en) * | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
JP4436928B2 (ja) | 2001-08-27 | 2010-03-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用 |
CA2463902A1 (en) * | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
AU2005316421B2 (en) * | 2004-12-17 | 2012-04-05 | The Trustees Of The University Of Pennsylvania | Stilbene derivatives and their use for binding and imaging amyloid plaques |
PT1999109E (pt) * | 2006-03-30 | 2012-03-16 | Univ Pennsylvania | Derivados de estirilpiridina e sua utilização para ligação e obtenção de imagens de placas amilóides |
JP2011503239A (ja) * | 2007-11-07 | 2011-01-27 | ジーイー・ヘルスケア・ベスローテン・ヴェンノーツハップ | 放射性医薬品の安定化 |
US20100310456A1 (en) * | 2009-06-04 | 2010-12-09 | General Electric Company | Imaging of myelin basic protein |
-
2010
- 2010-12-22 CN CN201080059126.6A patent/CN102762229B9/zh active Active
- 2010-12-22 EP EP10795010A patent/EP2515948A1/en not_active Withdrawn
- 2010-12-22 WO PCT/EP2010/070455 patent/WO2011076825A1/en active Application Filing
- 2010-12-22 UY UY33152A patent/UY33152A/es not_active Application Discontinuation
- 2010-12-22 BR BR112012015369A patent/BR112012015369A2/pt not_active Application Discontinuation
- 2010-12-22 KR KR1020127019237A patent/KR20120098914A/ko not_active Application Discontinuation
- 2010-12-22 US US13/518,197 patent/US20120328521A1/en not_active Abandoned
- 2010-12-22 TW TW099145355A patent/TW201138833A/zh unknown
- 2010-12-22 AU AU2010334929A patent/AU2010334929B2/en active Active
- 2010-12-22 EA EA201200940A patent/EA022447B1/ru not_active IP Right Cessation
- 2010-12-22 CA CA2785576A patent/CA2785576C/en active Active
- 2010-12-22 JP JP2012545313A patent/JP5774023B2/ja active Active
- 2010-12-22 AR ARP100104866A patent/AR079687A1/es unknown
- 2010-12-22 SG SG2012046710A patent/SG181903A1/en unknown
- 2010-12-22 MX MX2012007431A patent/MX336896B/es active IP Right Grant
-
2012
- 2012-06-21 IL IL220569A patent/IL220569A0/en unknown
- 2012-06-22 ZA ZA2012/04683A patent/ZA201204683B/en unknown
-
2013
- 2013-04-29 HK HK13105159.1A patent/HK1178064A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185793A1 (en) * | 2000-03-13 | 2003-10-02 | Felix Kratz | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
CN101123995A (zh) * | 2004-12-17 | 2008-02-13 | 宾夕法尼亚大学理事会 | 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途 |
Also Published As
Publication number | Publication date |
---|---|
SG181903A1 (en) | 2012-07-30 |
IL220569A0 (en) | 2012-08-30 |
CA2785576C (en) | 2017-12-05 |
WO2011076825A1 (en) | 2011-06-30 |
US20120328521A1 (en) | 2012-12-27 |
AU2010334929A1 (en) | 2012-07-05 |
AR079687A1 (es) | 2012-02-15 |
CA2785576A1 (en) | 2011-06-30 |
UY33152A (es) | 2011-07-29 |
JP2013515694A (ja) | 2013-05-09 |
JP5774023B2 (ja) | 2015-09-02 |
MX2012007431A (es) | 2012-10-15 |
EA201200940A1 (ru) | 2013-02-28 |
TW201138833A (en) | 2011-11-16 |
MX336896B (es) | 2016-02-05 |
ZA201204683B (en) | 2013-04-24 |
EA022447B1 (ru) | 2016-01-29 |
CN102762229A (zh) | 2012-10-31 |
BR112012015369A2 (pt) | 2018-01-23 |
AU2010334929B2 (en) | 2015-04-23 |
CN102762229B (zh) | 2014-11-12 |
HK1178064A1 (zh) | 2013-09-06 |
KR20120098914A (ko) | 2012-09-05 |
EP2515948A1 (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102762229B9 (zh) | 适用于用疏水pet试剂pet成像的配方 | |
EP2182988A2 (en) | Radiopharmaceutical composition | |
IL292333A (en) | Use of cyclodextrin as a radioactive stabilizer | |
JP6081997B2 (ja) | Petイメージングに適したフッ素化スチルベンの製剤 | |
NZ618977B2 (en) | Formulations of fluorinated stilbene suitable for pet imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1178064 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1178064 Country of ref document: HK |
|
CP01 | Change in the name or title of a patent holder |
Address after: Swiss Ma Telan Patentee after: Life Molecular Imaging Co.,Ltd. Address before: Swiss Ma Telan Patentee before: Bayer Pharma AG |
|
CP01 | Change in the name or title of a patent holder | ||
CI03 | Correction of invention patent |
Correction item: Claims Correct: Correct False: error Number: 46 Page: full text Volume: 30 |
|
CI03 | Correction of invention patent | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220621 Address after: Warwick, UK Patentee after: Biomolecular Imaging Co.,Ltd. Address before: Swiss Ma Telan Patentee before: Life Molecular Imaging Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121031 Assignee: BEIJING COTIMES BIOTECH CO.,LTD. Assignor: Biomolecular Imaging Co.,Ltd. Contract record no.: X2024990000153 Denomination of invention: Formula suitable for PET imaging using hydrophobic PET reagents Granted publication date: 20141112 License type: Exclusive License Record date: 20240416 |